Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Emergex Vaccines Holding Ltd
Emergex Vaccines Holding Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Recruitment
Dr Athanasios Papadopoulos joins Emergex as Chief Medical Officer
Oxford-based biotechnology company has appointed a clinical bio-pathology specialist
Research & Development
Emergex secures R&D facility in Oxfordshire
English biotech company now has overall internal control of all its vaccine development programmes
Infection Control
Emergex to develop novel vaccines against viral diseases
The biotech will collaborate with the Oswaldo Cruz Foundation to develop the vaccines
Pharmaceutical
Emergex files patent in US for novel pandemic flu vaccine
The patent, ‘Reverse Peptide Vaccines’, covers the use of peptides derived from human influenza A
Manufacturing
Emergex receives Innovate UK Grant to progress flu vaccine
The biotechnology company, which is aiming to find a new approach to vaccine development, has received a grant to progress its development programme
Recruitment
Emergex Vaccines appoints new member to board of directors
Recruitment
Emergex builds its Finance Team with two new recruits
Subscribe now